Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Clinical evidence RECONNECT trials: The FDA approval was based on two Phase 3 trials involving over 1,200 premenopausal women with HSDD: Significant increases in Female Sexual Function Index-desire domain scores Reduced distress related to low sexual desire Benefits maintained through 52-week open-label extension Rapid improvement when placebo patients switched to active treatment Earlier research: A 2006 study in premenopausal women with sexual arousal disorder found significantly more women reported moderate or high sexual desire after PT-141 compared to placebo (p=0.0114)
In addition to their biomedical potential, PVA/CH-SeNP composites were tested as an edible coating for Hollywood plum fruits, effectively extending postharvest storage life
Oleo Sci
Follow the session frequency advised by your practitioner
However, results are mixed
US$ 26.42
US$ 29.19
US$ 24.03
US$ 26.54
US$ 23.86
US$ 26.28
US$ 23.84
US$ 29.39
